April 5, 2021 07:50 AM EDTUpdated April 9, 01:41 PM
Financing

Pe­ter Thiel jumps aboard Al­loy's lat­est $75M round, adding some heft to the an­ti­body dis­cov­ery out­fit's nascent plat­form

Josh Sullivan

In the world of ven­ture cap­i­tal, names mat­ter — and few names are big­ger than Sil­i­con Val­ley pow­er play­er Pe­ter Thiel. Af­ter mak­ing a sprin­kling of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

In­cyte’s bet on Escient hits a snag as safe­ty is­sues ham­per Phase 2 chron­ic hives tri­al

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

Vir, Blue­jay in­vig­o­rate he­pati­tis D space with new da­ta

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times